The director, Center for Multiple Myeloma, Massachusetts General Hospital, discussed data seen with bb21217 in R/R MM.
This content originally appeared on our sister site, OncLive.
Investigators evaluated the BCMA-targeted chimeric antigen cell receptor (CAR T-cell) therapy bb21217 in patients with relapsed/refractory multiple myeloma in the phase 1 CRB-402 trial (NCT03274219).
Updated data demonstrated an overall response rate (ORR) of around 80% and rates were similar among patients who received prior treatment with a PI3K inhibitor. ORR was over 80% at the highest dose of bb21217 of 450 × 106 CAR+ T cells.
OncLive spoke with Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, to learn more about the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.
Regarding toxicity, no new safety signals were seen, though central nervous system toxicity was observed at grades 1 and 2, Raje noted. These toxicity findings were similar to findings reported with the use of idecabtagene vicleucel (ide-cel; Abecma) and ciltacabtagene autoleucel (cilta-cel; Carvykti), Raje concluded.